{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"contributor": "David Gelles contributed reporting.", "original": "By MICHAEL J. de la MERCED and ANDREW POLLACK", "person": [{"middlename": "J.", "firstname": "Michael", "lastname": "de la MERCED", "rank": 1, "role": "reported", "organization": ""}, {"rank": 2, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "AbbVie announces deal to buy Pharmacyclics for about $21 billion; Pharmacyclics makes cancer drug that may become one of best-selling treatments for the disease.", "type_of_material": "News", "word_count": "725", "lead_paragraph": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "pub_date": "2015-03-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Promising Cancer Drug", "print_headline": "AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Best-Selling Cancer Treatment"}, "snippet": "AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments.", "multimedia": [{"height": 126, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/03/05/business/dealbook/abbvie-to-pay-21-billion-for-pharmacyclics-maker-of-a-best-selling-cancer-treatment.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Pharmacyclics, Incorporated", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "AbbVie Inc", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Cancer", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Johnson & Johnson", "name": "organizations"}], "blog": [], "_id": "54f7da3738f0d8579fff6174", "source": "The New York Times"}